Of note, two patients harbored concurrent mutations in KRAS and PIK3CA. Importantly, the SCODA mutation detection platform demonstrated excellent concordance (18/19 cases tested, 95%) with a conventional quantitative PCR assay for KRAS performed on tumor tissue, a standard-of-care assessment for patients with metastatic CRC (Table 3). This evidence concerns the gene KRAS and colorectal carcinoma.